What is the growth forecast for the multiple myeloma therapeutics market?

The market is expected to grow at a CAGR of 7.8% from 2023 to 2028.

What are the key drivers of the multiple myeloma therapeutics market?

Increasing prevalence and rising awareness are key drivers of the multiple myeloma therapeutics market.

What are the major challenges in the multiple myeloma therapeutics market?

High treatment costs and limited accessibility are major challenges in the multiple myeloma therapeutics market.

Which regions are leading the multiple myeloma therapeutics market?

North America and Europe are leading the multiple myeloma therapeutics market.

Who are the top companies in the multiple myeloma therapeutics market?

Top companies include Johnson & Johnson, Celgene, and Amgen.

What are the future opportunities in the multiple myeloma therapeutics market?

Emerging markets and innovative therapies offer future opportunities in the multiple myeloma therapeutics market.

How is technology impacting the multiple myeloma therapeutics market?

Advances in genomics and precision medicine are transforming the multiple myeloma therapeutics market.

What is the regulatory landscape for the multiple myeloma therapeutics market?

Stringent regulations and safety protocols govern the multiple myeloma therapeutics market.

What is the future outlook for the multiple myeloma therapeutics market?

The future outlook is promising with increasing investment in research and development.

multiple myeloma therapeutics Market Growing at CAGR — 2026 Report

multiple myeloma therapeutics by Application (Hospitals, Clinics, Others), by Types (Chemotherapy, Radiation, Stem Cell Transplant, Other Supportive Treatments) Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $13400 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $13400 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

multiple myeloma therapeutics Market Overview

The multiple myeloma therapeutics market refers to the industry focused on developing and marketing treatments for multiple myeloma, a type of blood cancer. As the multiple myeloma therapeutics market size is expected to grow significantly, driven by increasing incidence rates and advancements in treatment options, understanding the growth outlook, market forecast, and industry expansion is crucial for stakeholders. The scope of this market encompasses various therapeutic approaches, including chemotherapy, targeted therapy, and immunotherapy, catering to the diverse needs of patients and healthcare providers. The current multiple myeloma therapeutics market size is approximately $12.6 billion, with a projected growth forecast indicating a compound annual growth rate (CAGR) of around 10% during the forecast period, driven by macro drivers such as an aging population and rising healthcare expenditure.

Loading chart…

Key forces shaping the industry include technology shifts towards more targeted and personalized therapies, regulations emphasizing safety and efficacy, and competitive intensity among market players. The largest region in the multiple myeloma therapeutics market is North America, while the fastest-growing region is Asia-Pacific, driven by increasing awareness and improving healthcare infrastructure. As the market continues to evolve, understanding these dynamics will be essential for C-suite executives, strategic planners, and business development teams to navigate the complex landscape and capitalize on emerging opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	13.40 billion
Revenue forecast in 2033	29.14 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Janssen Biotech, Inc.; Bristol-Myers Squibb; Novartis AG; Millennium Pharmaceuticals; Celgene Corporation; Kesios Therapeutics Limited; Amgen, Inc.; Genzyme Corporation; Juno Therapeutics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The multiple myeloma therapeutics market is poised for significant growth, driven by increasing disease prevalence and advancements in treatment options. The growth forecast for this market is promising, with the multiple myeloma therapeutics market size expected to expand substantially over the next few years.

Growth Drivers2 items

Advances in immunotherapy and stem cell transplantation are improving treatment outcomes, driving demand for effective therapies and contributing to the growth of the multiple myeloma therapeutics market.

Government initiatives and funding for cancer research are supporting the development of innovative treatments, further fueling the growth of the multiple myeloma therapeutics market size.

Restraints2 items

High development costs and stringent regulatory requirements are limiting the entry of new players in the multiple myeloma therapeutics market, thereby restraining market growth.

The patent expiration of key therapies is expected to lead to increased competition from generics, potentially hindering the growth of the multiple myeloma therapeutics market size.

Opportunities2 items

The growing demand for personalized medicine and targeted therapies presents opportunities for companies to develop innovative treatments and capitalize on the expanding multiple myeloma therapeutics market.

Emerging markets, particularly in Asia-Pacific, offer significant growth opportunities for multiple myeloma therapeutics market players due to improving healthcare infrastructure and increasing disease awareness.

Challenges2 items

The complex and heterogeneous nature of multiple myeloma poses significant challenges for developing effective treatments, requiring ongoing investment in research and development to address the unmet needs of patients.

The high cost of therapies and limited reimbursement options in some regions may restrict access to treatment, affecting the overall growth forecast of the multiple myeloma therapeutics market.

Market Segmentation

Loading chart…

The multiple myeloma therapeutics market can be segmented based on application, which refers to the specific uses of therapeutics in treating multiple myeloma. This segmentation category contributes significantly to the overall market size, as it determines the demand for therapeutics in various treatment settings. The application segment includes areas such as first-line treatment, second-line treatment, relapsed or refractory treatment, and maintenance therapy. Understanding the application segment is crucial for market players, as it helps them develop targeted therapeutics and marketing strategies, ultimately driving the growth of the multiple myeloma therapeutics segmentation.

Another key segmentation category in the multiple myeloma therapeutics market is types, which encompasses various subtypes of therapeutics, including proteasome inhibitors, immunomodulatory agents, histone deacetylase inhibitors, and monoclonal antibodies. Each subtype has distinct characteristics, mechanisms of action, and patient responses, making it essential to analyze them separately. The types segment plays a vital role in shaping the market landscape, as it influences the development of new therapeutics, clinical trials, and treatment guidelines. By examining the types segment, stakeholders can identify opportunities for innovation, assess competitive landscapes, and optimize their market strategies to capitalize on the growing demand for effective multiple myeloma treatments, thereby impacting the overall multiple myeloma therapeutics segmentation.

multiple myeloma therapeutics Segmentation Breakdown9 items

Application

Hospitals

Clinics

Others

Types

Chemotherapy

Radiation

Stem Cell Transplant

Other Supportive Treatments

Regional Insights

Loading chart…

The multiple myeloma therapeutics market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of novel therapies, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for North America include a mature ecosystem, high demographics of multiple myeloma patients, and a well-established infrastructure for clinical trials. In Europe, drivers include a strong regulatory framework, increasing awareness of multiple myeloma, and a large patient pool. Asia Pacific is driven by a growing middle-class population, increasing access to healthcare, and a rising prevalence of multiple myeloma. Latin America and Middle East & Africa are driven by government initiatives, growing demand for cancer treatments, and improving healthcare infrastructure.

The regional forecast indicates that Asia Pacific will experience the highest multiple myeloma therapeutics market growth, driven by emerging economies such as China and India. In contrast, Latin America and Middle East & Africa are expected to experience relatively slower growth due to infrastructure challenges and limited access to novel therapies.

Competitive Landscape

The multiple myeloma therapeutics market is moderately consolidated, driven by global players with a strong presence in the multiple myeloma therapeutics competitive landscape. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals. The market structure is characterized by a mix of global and local players, with the former focusing on innovation and the latter on regional expansion and localization.

Companies in this market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. The following companies have adopted distinct strategic focuses:

Janssen Biotech, Inc. - regional expansion

Bristol-Myers Squibb - innovation pipeline

Novartis AG - premium pricing

Millennium Pharmaceuticals - vertical integration

Celgene Corporation - local manufacturing

Kesios Therapeutics Limited - OEM tie-ups

Key multiple myeloma therapeutics Companies9 items

Janssen Biotech, Inc.

Bristol-Myers Squibb

Novartis AG

Millennium Pharmaceuticals

Celgene Corporation

Kesios Therapeutics Limited

Amgen, Inc.

Genzyme Corporation

Juno Therapeutics

Market Ecosystem

The multiple myeloma therapeutics ecosystem encompasses a complex network of participants, spanning upstream technology providers and suppliers to downstream channels and end users. This value chain analysis involves the creation and capture of value across various stages, from research and development to commercialization and patient treatment. The ecosystem can be broadly categorized into three segments: upstream, midstream, and downstream, with each segment comprising distinct roles and interactions.

Raw material/component suppliers — providing active pharmaceutical ingredients

OEMs / manufacturers — producing therapeutic drugs

Technology providers — developing innovative treatment platforms

Distributors / channel partners — ensuring market access and supply chain efficiency

Service providers / after-sales — offering patient support and monitoring services

Regulators/standards bodies — overseeing safety and efficacy standards

End users / buyers — receiving treatment and influencing demand

In the multiple myeloma therapeutics ecosystem, control points are primarily held by regulators and manufacturers, who influence adoption through approvals and supply chain management. Dependency risks arise from input constraints, such as limited access to active pharmaceutical ingredients, and standards, including stringent regulatory requirements. Switching costs and partnerships are also crucial, as companies may need to adapt to changing treatment landscapes and form alliances to remain competitive. Furthermore, the ecosystem differs by region, with varying levels of access to innovative treatments and distinct regulatory frameworks.

Recent Industry Insights

The multiple myeloma therapeutics industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as the collaboration between GlaxoSmithKline and Nektar Therapeutics, have been formed to advance the development of novel therapies. Furthermore, there have been notable mergers and acquisitions, including the acquisition of Celgene by Bristol Myers Squibb, which has expanded the company's portfolio of multiple myeloma treatments.

In addition, several product launches have taken place, including the introduction of selinexor, a novel XPO1 inhibitor. Regulatory changes, such as the FDA's approval of daratumumab in combination with lenalidomide and dexamethasone, have also shaped the industry landscape. The multiple myeloma therapeutics industry trends are expected to continue evolving, driven by advancements in immunotherapy and precision medicine, as well as shifts in consumer and enterprise trends towards more personalized and targeted treatments.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the multiple myeloma therapeutics market outlook. The market attractiveness is high due to the increasing prevalence of multiple myeloma and the availability of premium-priced therapies. The competitive intensity is moderate, with key players such as Johnson & Johnson and Celgene dominating the market. The long-term outlook is positive, driven by the growing demand for effective treatments and the emergence of innovative therapies.

The innovation landscape is dynamic, with ongoing research and development focused on targeted therapies and immunotherapies. The demand-supply balance is stable, with manufacturers expanding their production capacity to meet the growing demand. However, key risk factors such as pricing pressures and regulatory challenges may impact the market growth. Overall, the multiple myeloma therapeutics market outlook is promising, with opportunities for growth and innovation.

11 items

1. Executive Summary

2. multiple myeloma therapeutics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global multiple myeloma therapeutics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global multiple myeloma therapeutics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Clinics

6.1.3. Others

6.2. Global multiple myeloma therapeutics Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Chemotherapy

6.2.2. Radiation

6.2.3. Stem Cell Transplant

6.2.4. Other Supportive Treatments

6.3. Global multiple myeloma therapeutics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global multiple myeloma therapeutics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global multiple myeloma therapeutics Market by: Regions (Value)

8. Global multiple myeloma therapeutics Market Competition by Key Manufacturers

8.1. Global multiple myeloma therapeutics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global multiple myeloma therapeutics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Janssen Biotech, Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Bristol-Myers Squibb

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Novartis AG

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Millennium Pharmaceuticals

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Celgene Corporation

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Kesios Therapeutics Limited

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Amgen, Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Genzyme Corporation

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Juno Therapeutics

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global multiple myeloma therapeutics Market

Figure 4: Global multiple myeloma therapeutics Market: Drivers

Figure 5: Global multiple myeloma therapeutics Market: Challenges

Figure 6: Global multiple myeloma therapeutics Market: Trends

Figure 7: Global multiple myeloma therapeutics Market: Opportunity

Figure 8: Global multiple myeloma therapeutics Market: Restraint

Figure 9: Global multiple myeloma therapeutics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global multiple myeloma therapeutics Market Value (USD Million) By Region

Figure 15: Global multiple myeloma therapeutics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global multiple myeloma therapeutics Market Value (USD Million) By Region

Figure 23: Global multiple myeloma therapeutics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

71 items

Table 1: Market Segmentation Analysis

Table 2: Global multiple myeloma therapeutics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global multiple myeloma therapeutics Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global multiple myeloma therapeutics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global multiple myeloma therapeutics Market Value (USD Million) By Region

Table 10: Global multiple myeloma therapeutics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global multiple myeloma therapeutics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global multiple myeloma therapeutics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global multiple myeloma therapeutics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Janssen Biotech, Inc. Basic Information And Sales Area

Table 31: Janssen Biotech, Inc.. Products Portfolio

Table 32: Bristol-Myers Squibb Basic Information And Sales Area

Table 33: Bristol-Myers Squibb. Products Portfolio

Table 34: Novartis AG Basic Information And Sales Area

Table 35: Novartis AG. Products Portfolio

Table 36: Millennium Pharmaceuticals Basic Information And Sales Area

Table 37: Millennium Pharmaceuticals. Products Portfolio

Table 38: Celgene Corporation Basic Information And Sales Area

Table 39: Celgene Corporation. Products Portfolio

Table 40: Kesios Therapeutics Limited Basic Information And Sales Area

Table 41: Kesios Therapeutics Limited. Products Portfolio

Table 42: Amgen, Inc. Basic Information And Sales Area

Table 43: Amgen, Inc.. Products Portfolio

Table 44: Genzyme Corporation Basic Information And Sales Area

Table 45: Genzyme Corporation. Products Portfolio

Table 46: Juno Therapeutics Basic Information And Sales Area

Table 47: Juno Therapeutics. Products Portfolio

Table 48: Global Market Value (USD Million) (2025-2032) By Application

Table 49: Global Market Share (%) By Application (2032)

Table 50: Global Market Value (USD Million) (2025-2032) By Types

Table 51: Global Market Share (%) By Types (2032)

Table 52: Global multiple myeloma therapeutics Market Value (USD Million) By Region

Table 53: Global multiple myeloma therapeutics Market Share (%) By Region (2025-2032)

Table 54: North America Market Value (USD Million) (2025-2032) By Country

Table 55: North America Market Value (USD Million) (2025-2032) By Application

Table 56: North America Market Value (USD Million) (2025-2032) By Types

Table 57: Europe Market Value (USD Million) (2025-2032) By Country

Table 58: Europe Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Types

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 61: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 63: South America Market Value (USD Million) (2025-2032) By Country

Table 64: South America Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Types

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 67: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 69: Research Programs/Design For This Report

Table 70: Key Data Information From Secondary Sources

Table 71: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

multiple myeloma therapeutics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	13.40 billion
Revenue forecast in 2033	29.14 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Janssen Biotech, Inc.; Bristol-Myers Squibb; Novartis AG; Millennium Pharmaceuticals; Celgene Corporation; Kesios Therapeutics Limited; Amgen, Inc.; Genzyme Corporation; Juno Therapeutics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Government initiatives and funding for cancer research are supporting the development of innovative treatments, further fueling the growth of the multiple myeloma therapeutics market size.

Restraints2 items

High development costs and stringent regulatory requirements are limiting the entry of new players in the multiple myeloma therapeutics market, thereby restraining market growth.

The patent expiration of key therapies is expected to lead to increased competition from generics, potentially hindering the growth of the multiple myeloma therapeutics market size.

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

multiple myeloma therapeutics Segmentation Breakdown9 items

Application

Hospitals

Clinics

Others

Types

Chemotherapy

Radiation

Stem Cell Transplant

Other Supportive Treatments

Regional Insights

Loading chart…

Competitive Landscape

Janssen Biotech, Inc. - regional expansion

Bristol-Myers Squibb - innovation pipeline

Novartis AG - premium pricing

Millennium Pharmaceuticals - vertical integration

Celgene Corporation - local manufacturing

Kesios Therapeutics Limited - OEM tie-ups

Key multiple myeloma therapeutics Companies9 items

Janssen Biotech, Inc.

Bristol-Myers Squibb

Novartis AG

Millennium Pharmaceuticals

Celgene Corporation

Kesios Therapeutics Limited

Amgen, Inc.

Genzyme Corporation

Juno Therapeutics

Market Ecosystem

Raw material/component suppliers — providing active pharmaceutical ingredients

OEMs / manufacturers — producing therapeutic drugs

Technology providers — developing innovative treatment platforms

Distributors / channel partners — ensuring market access and supply chain efficiency

Service providers / after-sales — offering patient support and monitoring services

Regulators/standards bodies — overseeing safety and efficacy standards

End users / buyers — receiving treatment and influencing demand

Recent Industry Insights

Analyst Overview

Table of Contents